{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:33:13Z","timestamp":1789421593853,"version":"build-2803163510"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ejphar.2026.179017","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T15:39:27Z","timestamp":1779550767000},"page":"179017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Metformin-associated lactic acidosis: Bridging pharmacokinetic determinants, metabolic pathways, and clinical outcomes"],"prefix":"10.1016","volume":"1029","author":[{"given":"Km Rukhsar","family":"Anwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5561-9308","authenticated-orcid":false,"given":"Mohd Muazzam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Badruddeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashmun","family":"Nisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehraz Mehmood","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.179017_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.resp.2020.103586","article-title":"Increased ratio of P [va] CO2 to C [av] O2 without global hypoxia: the case of metformin-induced lactic acidosis","volume":"285","author":"Andreis","year":"2021","journal-title":"Respir. Physiol. Neurobiol."},{"key":"10.1016\/j.ejphar.2026.179017_bib2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/MJT.0b013e318197eab6","article-title":"The MALAdy of metformin poisoning: is CVVH the cure?","volume":"17","author":"Arroyo","year":"2010","journal-title":"Am. J. Therapeut."},{"key":"10.1016\/j.ejphar.2026.179017_bib3","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199602293340906","article-title":"Metformin","volume":"334","author":"Bailey","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.179017_bib4","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.3390\/jcm9051346","article-title":"Chronic kidney disease management in general practice: a focus on inappropriate drugs prescriptions","volume":"9","author":"Barbieri","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2026.179017_bib5","doi-asserted-by":"crossref","first-page":"e1194","DOI":"10.1097\/CCM.0000000000004589","article-title":"A study of associations between plasma metformin concentration, lactic acidosis, and mortality in an emergency hospitalization context","volume":"48","author":"Bennis","year":"2020","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.ejphar.2026.179017_bib6","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1097\/CCM.0000000000001002","article-title":"Extracorporeal treatment for metformin poisoning: systematic review and recommendations from the EXTRIP workgroup","volume":"43","author":"Calello","year":"2015","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.ejphar.2026.179017_bib7","doi-asserted-by":"crossref","first-page":"e541","DOI":"10.1097\/CCM.0000000000001353","article-title":"Prevalence and impact of unknown diabetes in the ICU","volume":"43","author":"Carpenter","year":"2015","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.ejphar.2026.179017_bib8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/eci.12036","article-title":"Type 2 diabetes and 1\u2010year mortality in intensive care unit patients","volume":"43","author":"Christiansen","year":"2013","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2026.179017_bib9","first-page":"4059","article-title":"Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus","volume":"81","author":"Cusi","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2026.179017_bib10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0002-9343(96)00353-1","article-title":"An overview of metformin in the treatment of type 2 diabetes mellitus","volume":"102","author":"Davidson","year":"1997","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejphar.2026.179017_bib11","doi-asserted-by":"crossref","first-page":"8636","DOI":"10.1038\/s41598-025-87624-1","article-title":"Efficacy of continuous venovenous hemodiafiltration in patients with metformin associated lactic acidosis and acute kidney injury","volume":"15","author":"De Simone","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2026.179017_bib12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.7326\/0003-4819-131-4-199908170-00008","article-title":"Pharmacologic therapy for type 2 diabetes mellitus","volume":"131","author":"DeFronzo","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejphar.2026.179017_bib13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","article-title":"Metformin-associated lactic acidosis: current perspectives on causes and risk","volume":"65","author":"DeFronzo","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2026.179017_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfaf286","article-title":"Regional citrate anticoagulation ensures safe and effective kidney replacement therapy in metformin-associated lactic acidosis","volume":"18","author":"Di Mario","year":"2025","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.ejphar.2026.179017_bib15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40264-013-0038-6","article-title":"The role of metformin in metformin-associated lactic acidosis (MALA): case series and formulation of a model of pathogenesis","volume":"36","author":"Duong","year":"2013","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejphar.2026.179017_bib16","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2026.179017_bib17","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.2337\/dc13-3023","article-title":"Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study","volume":"37","author":"Eppenga","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2026.179017_bib18","doi-asserted-by":"crossref","DOI":"10.1186\/cc9376","article-title":"Outcome of severe lactic acidosis associated with metformin accumulation","volume":"14","author":"Friesecke","year":"2010","journal-title":"Crit. Care"},{"key":"10.1016\/j.ejphar.2026.179017_bib19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","article-title":"Clinical pharmacokinetics of metformin","volume":"50","author":"Graham","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2026.179017_bib20","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41581-024-00823-3","article-title":"Drug stewardship in chronic kidney disease to achieve effective and safe medication use","volume":"20","author":"Hall","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejphar.2026.179017_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/bcpt.13986","article-title":"Inappropriate prescribing in patients with kidney disease: a rapid review of prevalence, associated clinical outcomes, and impact of interventions","volume":"134","author":"Hamzaei","year":"2024","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2026.179017_bib22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1089\/dia.2014.0203","article-title":"Helicobacter pylori infection decreases metformin tolerance in patients with type 2 diabetes mellitus","volume":"17","author":"Huang","year":"2015","journal-title":"Diabetes Technol. Therapeut."},{"key":"10.1016\/j.ejphar.2026.179017_bib23","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41591-018-0159-7","article-title":"Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase","volume":"24","author":"Hunter","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2026.179017_bib24","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2337\/diaspect.25.3.154","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the american diabetes association (ADA) and the european association for the study of diabetes (EASD)","volume":"25","author":"Inzucchi","year":"2012","journal-title":"Diabetes Spectr."},{"key":"10.1016\/j.ejphar.2026.179017_bib25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.7326\/0003-4819-92-2-227","article-title":"Lactate homeostasis and lactic acidosis","volume":"92","author":"Kreisberg","year":"1980","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejphar.2026.179017_bib26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2165\/11536790-000000000-00000","article-title":"Lactic acidosis induced by metformin: incidence, management and prevention","volume":"33","author":"Lalau","year":"2010","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejphar.2026.179017_bib27","first-page":"285","article-title":"Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination","volume":"27","author":"Lalau","year":"1989","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"10.1016\/j.ejphar.2026.179017_bib28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1463-1326.2003.00241.x","article-title":"Measurement of metformin concentration in erythrocytes: clinical implications. Diabetes","volume":"5","author":"Lalau","year":"2003","journal-title":"Obes. Metabol."},{"key":"10.1016\/j.ejphar.2026.179017_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e8525","article-title":"Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study","volume":"346","author":"Lapi","year":"2013","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejphar.2026.179017_bib30","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1053\/j.ajkd.2023.09.012","article-title":"Kidney function decline and serious adverse drug reactions in patients with CKD","volume":"83","author":"Laville","year":"2024","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejphar.2026.179017_bib31","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ajcp\/80.4.484","article-title":"Definition of clinically relevant lactic acidosis in patients with internal diseases","volume":"80","author":"Luft","year":"1983","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ejphar.2026.179017_bib32","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature13270","article-title":"Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase","volume":"510","author":"Madiraju","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.179017_bib34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000471917","article-title":"Metformin-associated lactic acidosis undergoing renal replacement therapy in intensive care units: a five-million population-based study in the North-West of Italy","volume":"44","author":"Mariano","year":"2017","journal-title":"Blood Purif."},{"key":"10.1016\/j.ejphar.2026.179017_bib33","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s40620-020-00941-8","article-title":"Metformin, chronic nephropathy, and lactic acidosis: a multi-faceted issue for the nephrologist","volume":"34","author":"Mariano","year":"2021","journal-title":"J. Nephrol."},{"key":"10.1016\/j.ejphar.2026.179017_bib35","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s40620-016-0267-8","article-title":"Metformin associated lactic acidosis (MALA): clinical profiling and management","volume":"29","author":"Moioli","year":"2016","journal-title":"J. Nephrol."},{"key":"10.1016\/j.ejphar.2026.179017_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000528252","article-title":"Metformin's role in hyperlactatemia and lactic acidosis in ICU patients: a systematic review","volume":"108","author":"Mueller","year":"2023","journal-title":"Pharmacology"},{"key":"10.1016\/j.ejphar.2026.179017_bib37","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0002-9343(70)90117-8","article-title":"Lactic acidosis","volume":"48","author":"Oliva","year":"1970","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejphar.2026.179017_bib38","doi-asserted-by":"crossref","first-page":"841","DOI":"10.34067\/KID.0000000000000447","article-title":"Polypharmacy in patients with CKD: a systematic review and meta-analysis","volume":"5","author":"Oosting","year":"2024","journal-title":"Kidney"},{"key":"10.1016\/j.ejphar.2026.179017_bib39","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1042\/bj3480607","article-title":"Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain","volume":"348","author":"Owen","year":"2000","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejphar.2026.179017_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2026.178560","article-title":"Safety of metformin in chronic kidney disease and type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"1015","author":"Pati\u00f1o-Cardona","year":"2026","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179017_bib41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF00562061","article-title":"Pharmacokinetics of metformin after intravenous and oral administration to man","volume":"16","author":"Pentik\u00e4inen","year":"1979","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179017_bib42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3390\/metabo14040186","article-title":"Metformin and the liver: unlocking the full therapeutic potential","volume":"14","author":"Perazza","year":"2024","journal-title":"Metabolites"},{"key":"10.1016\/j.ejphar.2026.179017_bib43","doi-asserted-by":"crossref","first-page":"R22","DOI":"10.1186\/cc8885","article-title":"Oxygen consumption is depressed in patients with lactic acidosis due to biguanide intoxication","volume":"14","author":"Protti","year":"2010","journal-title":"Crit. Care"},{"key":"10.1016\/j.ejphar.2026.179017_bib44","article-title":"Metformin use and metformin-associated lactic acidosis in intensive care unit patients with diabetes","volume":"11","author":"Rajasurya","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.ejphar.2026.179017_bib45","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1001\/jama.2019.13206","article-title":"Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function","volume":"322","author":"Roumie","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2026.179017_bib46","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/archinte.163.21.2594","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis","volume":"163","author":"Salpeter","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ejphar.2026.179017_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002967.pub3","article-title":"Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus","author":"Salpeter","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejphar.2026.179017_bib48","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00003088-199630050-00003","article-title":"Clinical pharmacokinetics of metformin","volume":"30","author":"Scheen","year":"1996","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2026.179017_bib49","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.4239\/wjd.v15.i6.1178","article-title":"Metformin-associated lactic acidosis: a mini review of pathophysiology, diagnosis and management in critically ill patients","volume":"15","author":"See","year":"2024","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.ejphar.2026.179017_bib50","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/CCM.0b013e3181a02490","article-title":"Metformin-associated lactic acidosis: a prognostic and therapeutic study","volume":"37","author":"Seidowsky","year":"2009","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.ejphar.2026.179017_bib51","article-title":"Evaluation of drug-related problems in chronic kidney disease patients","volume":"14","author":"Shouqair","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.ejphar.2026.179017_bib52","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1016\/j.jemermed.2023.11.017","article-title":"Metformin-associated lactic acidosis-is this on your radar?","volume":"66","author":"Simon","year":"2024","journal-title":"J. Emerg. Med."},{"key":"10.1016\/j.ejphar.2026.179017_bib53","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/cpt1978246683","article-title":"Disposition of metformin (N, N\u2010dimethylbiguanide) in man","volume":"24","author":"Sirtori","year":"1978","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2026.179017_bib54","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2337\/diacare.22.6.925","article-title":"Incidence of lactic acidosis in metformin users","volume":"22","author":"Stang","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2026.179017_bib55","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/clpt.2012.210","article-title":"The effect of novel promoter variants in MATE1 and MATE2-K on the pharmacokinetics and pharmacodynamics of metformin","volume":"93","author":"Stocker","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2026.179017_bib56","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2337\/diacare.20.6.925","article-title":"Contraindications to metformin therapy in patients with NIDDM","volume":"20","author":"Sulkin","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2026.179017_bib57","article-title":"Renal manifestations of metformin-associated lactic acidosis: new findings","volume":"13","author":"Tajdini","year":"2024","journal-title":"J. Ren. Inj. Prev."},{"key":"10.1016\/j.ejphar.2026.179017_bib58","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3390\/jcm13020343","article-title":"Drug-related problems and sick day management considerations for medications that contribute to the risk of acute kidney injury","volume":"13","author":"Truong","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2026.179017_bib59","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/15563650.2013.860985","article-title":"Metformin accumulation: lactic acidosis and high plasmatic metformin levels in a retrospective case series of 66 patients on chronic therapy","volume":"52","author":"Vecchio","year":"2014","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.ejphar.2026.179017_bib60","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/cc9404","article-title":"Metformin-induced lactic acidosis: no one left behind","volume":"15","author":"Vecchio","year":"2011","journal-title":"Crit. Care"},{"key":"10.1016\/j.ejphar.2026.179017_bib61","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s12882-024-03829-y","article-title":"Medications for community pharmacists to dose adjust or avoid to enhance prescribing safety in individuals with advanced chronic kidney disease: a scoping review and modified Delphi","volume":"25","author":"Wilson","year":"2024","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.ejphar.2026.179017_bib62","article-title":"Systematic review and meta-analysis of current guidelines, and their evidence base, on risk of renal function after administration of contrast medium for diabetic patients receiving metformin","volume":"12","author":"Xu","year":"2025","journal-title":"Front. Med."},{"key":"10.1016\/j.ejphar.2026.179017_bib63","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.2169\/internalmedicine.2707-23","article-title":"Metformin-associated lactic acidosis induced by excessive alcohol consumption","volume":"63","author":"Yamagishi","year":"2024","journal-title":"Intern. Med."},{"key":"10.1016\/j.ejphar.2026.179017_bib64","article-title":"Metformin use despite contraindications in metformin-associated lactic acidosis","volume":"104","author":"Yang","year":"2025","journal-title":"Medicine"},{"key":"10.1016\/j.ejphar.2026.179017_bib65","article-title":"Clinical presentations and prognosis of metformin-associated lactic acidosis patients in the intensive care unit: a 20-year survey","volume":"101","author":"Yang","year":"2022","journal-title":"Medicine"},{"key":"10.1016\/j.ejphar.2026.179017_bib66","first-page":"1063","article-title":"Clinical implications of transporter-mediated drug-drug interactions with metformin","volume":"55","author":"Yin","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2026.179017_bib67","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.sapharm.2025.05.005","article-title":"Deprescribing tools and guidelines in chronic kidney disease: a scoping review","volume":"21","author":"Zidan","year":"2025","journal-title":"Res. Soc. Adm. Pharm."},{"key":"10.1016\/j.ejphar.2026.179017_bib68","first-page":"325","article-title":"Functional characterization of the human organic cation transporter 2 variant p.Ala270Ser","volume":"19","author":"Zolk","year":"2009","journal-title":"Pharmacogenet. Genom."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926004991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926004991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:10:20Z","timestamp":1784808620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926004991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":68,"alternative-id":["S0014299926004991"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179017","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin-associated lactic acidosis: Bridging pharmacokinetic determinants, metabolic pathways, and clinical outcomes","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"179017"}}